Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*

2003 ◽  
Vol 31 (3) ◽  
pp. 834-840 ◽  
Author(s):  
Jean-Louis Vincent ◽  
Derek C. Angus ◽  
Antonio Artigas ◽  
Andre Kalil ◽  
Bruce R. Basson ◽  
...  
Keyword(s):  
Organ Dysfunction ◽  
Drotrecogin Alfa ◽  
Drotrecogin Alfa Activated ◽  
Prowess Trial

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

2003 ◽  
Vol 29 (6) ◽  
pp. 894-903 ◽  
Author(s):  
Jean-François Dhainaut ◽  
◽  
Pierre-François Laterre ◽  
Jonathan M. Janes ◽  
Gordon R. Bernard ◽  
...  
Keyword(s):  
Severe Sepsis ◽  
Organ Dysfunction ◽  
Drotrecogin Alfa ◽  
Multiple Organ ◽  
Multiple Organ Dysfunction ◽  
Drotrecogin Alfa Activated ◽  
Prowess Trial

Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis

2004 ◽  
Vol 53 (10) ◽  
pp. 528-533 ◽  
Author(s):  
M. Brueckmann ◽  
U. Hoffmann ◽  
E. Dvortsak ◽  
S. Lang ◽  
J. J. Kaden ◽  
...  
Keyword(s):  
Severe Sepsis ◽  
Drotrecogin Alfa ◽  
Mononuclear Cells ◽  
Nf Kappa B ◽  
Drotrecogin Alfa Activated

scholarly journals Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis

Critical Care ◽  
2006 ◽  
Vol 10 (3) ◽  
Author(s):  
Jean-Louis Vincent ◽  
James O'Brien ◽  
Arthur Wheeler ◽  
Xavier Wittebole ◽  
Rekha Garg ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Severe Sepsis ◽  
Drotrecogin Alfa ◽  
Clinical Trial Database ◽  
Drotrecogin Alfa Activated
Sign in / Sign up

Export Citation Format

Share Document